跳至主要内容
临床试验/NCT01266759
NCT01266759已完成不适用

Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia

Mansoura University1 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
95
试验地点
1
主要终点
Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.

研究概览

简要总结

To compare the efficacy of a combined contraceptive vaginal ring (NuvaRing) and oral Norethisterone Acetate in treatment of Idiopathic heavy menstrual bleeding during fertile age

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with heavy menstrual bleeding based on PBAC score over 185 (mean of two control cycles)and desire contraception

排除标准

  • Menorrhagia of endocrine or systemic origin
  • other pathology e.g. patients with fibroids of any size, adenomyosis, endometriosis, pelvic inflammatory disease.

研究组 & 干预措施

NuvaRing

Experimental

For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.

干预措施: NuvaRing (Drug)

Norethisterone Acetate

Active Comparator

Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment

干预措施: Norethisterone Acetate tablets - 5mg (Drug)

结局指标

主要结局

Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.

次要结局

  • Haemoglobin and serum ferritin at the end of study (cycle 3)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验